|
1
|
Noone AM, Howlader N, Krapcho M, Miller D,
Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al:
SEER cancer statistics review, 1975-2015. National Cancer
Institute; Bethesda, MD: https://seer.cancer.gov/csr/1975_2015/,
based on November 2017, SEER data submission, posted to the SEER
web site. Accessed September 10, 2018.
|
|
2
|
Jiang W, Cai G, Hu PC and Wang Y:
Personalized medicine in non-small cell lung cancer: A review from
a pharmacogenomics perspective. Acta Pharm Sin B. 8:530–538. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang JC, Ren YG, Zhao J, Long F, Chen JY
and Jiang Z: Shikonin enhances sensitization of gefitinib against
wild-type EGFR non-small cell lung cancer via inhibition
PKM2/stat3/cyclinD1 signal pathway. Life Sci. 204:71–77. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi T, Koizumi T, Agatsuma T, Yasuo
M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T and
Ohura N: A phase II trial of erlotinib in patients with EGFR
wild-type advanced non-small-cell lung cancer. Cancer Chemother
Pharmacol. 69:1241–1246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Su SF, Li M, Geng YC, Yang WG, Ma Z, Li
QS, Hu YX, Ou Yang WW, Liu LF and Lu B: Randomized phase II study
of pemetrexed-cisplatin or docetaxel-cisplatin plus thoracic
intensity-modulated radiation therapy in patients with stage IV
lung adenocarcinoma. Am J Cancer Res. 9:1235–1245. 2019.PubMed/NCBI
|
|
6
|
Toole BP and Slomiany MG: Hyaluronan: A
constitutive regulator of chemoresistance and malignancy in cancer
cells. Semin Cancer Biol. 18:244–250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen C, Zhao S, Karnad A and Freeman JW:
The biology and role of CD44 in cancer progression: Therapeutic
implications. J Hematol Oncol. 11:642018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park NR, Cha JH, Jang JW, Bae SH, Jang B,
Kim JH, Hur W, Choi JY and Yoon SK: Synergistic effects of CD44 and
TGF-β1 through AKT/GSK-3β/β-catenin signaling during
epithelial-mesenchymal transition in liver cancer cells. Biochem
Biophys Res Commun. 477:568–574. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xu H and Wu K, Tian Y, Liu Q, Han N, Yuan
X, Zhang L, Wu GS and Wu K: CD44 correlates with
clinicopathological characteristics and is upregulated by EGFR in
breast cancer. Int J Oncol. 49:1343–1350. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grass GD, Tolliver LB, Bratoeva M and
Toole BP: CD147, CD44, and the epidermal growth factor receptor
(EGFR) signaling pathway cooperate to regulate breast epithelial
cell invasiveness. J Biol Chem. 288:26089–26104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wobus M, Rangwala R, Sheyn I, Hennigan R,
Coila B, Lower EE, Yassin RS and Sherman LS: CD44 associates with
EGFR and erbB2 in metastasizing mammary carcinoma cells. Appl
Immunohistochem Mol Morphol. 10:34–39. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim S, Kil WH, Lee J, Oh SJ, Han J, Jeon
M, Jung T, Lee SK, Bae SY, Lee HC, et al: Zerumbone suppresses
EGF-induced CD44 expression through the inhibition of STAT3 in
breast cancer cells. Oncol Rep. 32:2666–2672. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perez A, Neskey DM, Wen J, Pereira L,
Reategui EP, Goodwin WJ, Carraway KL and Franzmann EJ: CD44
interacts with EGFR and promotes head and neck squamous cell
carcinoma initiation and progression. Oral Oncol. 49:306–313. 2013.
View Article : Google Scholar :
|
|
14
|
Wang W, Zhang H, Liu S, Kim CK, Xu Y,
Hurley LA, Nishikawa R, Nagane M, Hu B, Stegh AH, et al:
Internalized CD44s splice isoform attenuates EGFR degradation by
targeting Rab7A. Proc Natl Acad Sci USA. 114:8366–8371. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Morath I, Jung C, Lévêque R, Linfeng C,
Toillon RA, Warth A and Orian-Rousseau V: Differential recruitment
of CD44 isoforms by ErbB ligands reveals an involvement of CD44 in
breast cancer. Oncogene. 37:1472–1484. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Meran S, Luo DD, Simpson R, Martin J,
Wells A, Steadman R and Phillips AO: Hyaluronan facilitates
transforming growth factor-β1-dependent proliferation via CD44 and
epidermal growth factor receptor interaction. J Biol Chem.
286:17618–17630. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
18
|
Chohan TA, Qayyum A, Rehman K, Tariq M and
Akash MSH: An insight into the emerging role of cyclin-dependent
kinase inhibitors as potential therapeutic agents for the treatment
of advanced cancers. Biomed Pharmacother. 107:1326–1341. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu SG and Shih JY: Management of acquired
resistance to EGFR TKI-targeted therapy in advanced non-small cell
lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park K, Vansteenkiste J, Lee KH,
Pentheroudakis G, Zhou C, Prabhash K, Seto T, Voon PJ, Tan DSW,
Yang JCH, et al: Pan-Asian adapted ESMO clinical practice
guidelines for the management of patients with locally-advanced
unresectable non-small-cell lung cancer: A KSMO-ESMO initiative
endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS. Ann Oncol.
31:191–201. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Su C, Zhou F, Shen J, Zhao J and O'Brien
M: Treatment of elderly patients or patients who are performance
status 2 (PS2) with advanced non-small cell lung cancer without
epidermal growth factor receptor (EGFR) mutations and anaplastic
lymphoma kinase (ALK) translocations-Still a daily challenge. Eur J
Cancer. 83:266–278. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang TH, Wu TH, Guo YH, Li TL, Chan YL
and Wu CJ: The concurrent treatment of Scutellaria baicalensis
Georgi enhances the therapeutic efficacy of cisplatin but also
attenuates chemotherapy-induced cachexia and acute kidney injury. J
Ethnopharmacol. 243:1120752019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Roudi R, Madjd Z, Korourian A, Mehrazma M,
Molanae S, Sabet MN and Shariftabrizi A: Clinical significance of
putative cancer stem cell marker CD44 in different histological
subtypes of lung cancer. Cancer Biomark. 14:457–467. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Quan YH, Lim JY, Choi BH, Choi Y, Choi YH,
Park JH and Kim HK: Self-targeted knockdown of CD44 improves
cisplatin sensitivity of chemoresistant non-small cell lung cancer
cells. Cancer Chemother Pharmacol. 83:399–410. 2019. View Article : Google Scholar
|
|
26
|
Zheng Z, Shao N, Weng H, Li W, Zhang J,
Zhang L, Yang L and Ye S: Correlation between epidermal growth
factor receptor and tumor stem cell markers CD44/CD24 and their
relationship with prognosis in breast invasive ductal carcinoma.
Med Oncol. 32:2752015. View Article : Google Scholar
|
|
27
|
Rho JH, Ladd JJ, Li CI, Potter JD, Zhang
Y, Shelley D, Shibata D, Coppola D, Yamada H, Toyoda H, et al:
Protein and glycomic plasma markers for early detection of adenoma
and colon cancer. Gut. 67:473–484. 2018. View Article : Google Scholar
|
